Abstract:INTRODUCTION:The RNA-guided nuclease Cas9 can be used as a programmable transcription activator, but there is still room for improvement in its effectiveness in eukaryotes, and its potential in cancer genetic therapy has been poorly investigated. OBJECTIVES:We aim to construct optimized CRISPRa tools and detect their potential role in cancer therapy by screening 9aa-TAD. METHODS:We selected a range of transcriptional coactivators for programmable activation and analyzed their effects on the expression of multiple endogenous genes using Flow cytometry and qRT-PCR. In order to improve the activation capacity of the CRISPRa tool, we fused the coactivators with the efficient dCas9-VPR system to construct a new activation system. Utilize RNA-seq to assess the activation specificity of genome-wide. To evaluate the value of the newly constructed activation system in cancer gene therapy, we activated the expression of the tumor suppressor genes PER2 and ZNF382, and performed changes in cancer cell proliferation qRT-PCR and clonal formation analysis. RESULTS:In this study, we screened the NHR module from C. elegans, which demonstrated a high transcription activation capacity with a compact size compared to VP64. We successfully demonstrated its efficiency in activating endogenous genes in mammalian cells. Furthermore, we developed an enhanced fused variant called NHR-VP64-p65-Rta (NVPR), which showed even higher efficiency compared to the previously established VPR module, making it an effective CRISPRa tool. The dCas9-NVPR complex also exhibited high specificity on a genome-wide scale. Finally, we utilized the dCas9-NVPR tool to restore the expression of tumor suppressor genes PER2 and ZNF382, effectively inhibiting the malignant phenotype of cancer cells. CONCLUSION:We have successfully developed and demonstrated a breakthrough CRISPRa tool with promising implications for cancer genetic therapy. This innovation expands the range of available gene editing tools and further validates the immense potential of CRISPR-based approaches in precision medicine.

Rational Design of Mini-Cas9 for Transcriptional Activation

MiniCAFE, a CRISPR/Cas9-based compact and potent transcriptional activator, elicits gene expression in vivo

A strategy for Cas13 miniaturization based on the structure and AlphaFold

Rationally designed Campylobacter jejuni Cas9 enables efficient gene activation and base editing

Structural basis for the activation of a compact CRISPR-Cas13 nuclease

Rationally engineered Staphylococcus aureus Cas9 nucleases with high genome-wide specificity

A Compact Cas9 Ortholog from Staphylococcus Auricularis (sauricas9) Expands the DNA Targeting Scope.

DNA targeting by compact Cas9d and its resurrected ancestor

Integration and Exchange of Split Dcas9 Domains for Transcriptional Controls in Mammalian Cells

Discovery and engineering of small SlugCas9 with broad targeting range and high specificity and activity

Engineered miniature CRISPR-Cas system for mammalian genome regulation and editing

Mini and Enhanced CRISPR Activators for Cancer Therapies

Fine-Tuning Cas9 Activity with a Cognate Inhibitor AcrIIA4 to Improve Genome Editing in <i>Streptomyces</i>

Programmable repression and activation of bacterial gene expression using an engineered CRISPR-Cas system

Molecular Basis and Engineering of Miniature Cas12f with C-rich PAM Specificity

Programmed genome editing by a miniature CRISPR-Cas12f nuclease

Engineering Miniature CRISPR-Cas Un1Cas12f1 for Efficient Base Editing

Engineering of a compact, high-fidelity EbCas12a variant that can be packaged with its crRNA into an all-in-one AAV vector delivery system

Gene Activation by a CRISPR-assisted Trans Enhancer

Advances in miniature CRISPR-Cas proteins and their applications in gene editing

Multiplexed activation in mammalian cells using a split-intein CRISPR/Cas12a based synthetic transcription factor